Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice

British Journal of Cancer

Volumn 97, Issue 2, 2007, Pages 183-193

  Lorch, G ^a   Gilmore, J L ^b   Koltz, P F ^b   Gonterman, R M ^b   Laughner, R ^b   Lewis, D A ^c,d   Konger, R L ^c,d   Nadella, K S ^a   Toribio, R E ^a   Rosol, T J ^a   Foley, J ^b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anilinoquinazolines; Gefitinib; Hypercalcaemia; Lung cancer; PTHrP; ZD1839

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; AMPHIREGULIN; AMPHIREGULIN ANTIBODY; CALCIUM; CREATININE; CYCLIC AMP; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GEFITINIB; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MESSENGER RNA; PARATHYROID HORMONE RELATED PROTEIN; PLACEBO; PROTEIN ANTIBODY; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; CALCIUM BLOOD LEVEL; CANCER CELL CULTURE; CANCER SIZE; CONTROLLED STUDY; CREATININE URINE LEVEL; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYPERCALCEMIA; HYPERCALCEMIA OF MALIGNANCY; LUNG SQUAMOUS CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PARANEOPLASTIC SYNDROME; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR XENOGRAFT; UPREGULATION; URINE LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; HYPERCALCEMIA; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PARATHYROID HORMONE-RELATED PROTEIN; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RNA, MESSENGER; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34447301304     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603828     Document Type: Article

References (50)

1. Aklilu F, Gladu J, Goltzman D, Rabbani SA (2000) Role of mitogen-activated protein kinases in the induction of parathyroid hormone-related peptide. Cancer Res 60: 1753-1760
2. Aklilu F, Park M, Goltzman D, Rabbani SA (1997) Induction of parathyroid hormone-related peptide by the Ras oncogene: role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy. Cancer Res 57: 4517-4522
3. Baselga J (2002) Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. J Clin Oncol 20: 2217-2219
4. Bender RA, Hansen H (1974) Hypercalcemia in bronchogenic carcinoma. A prospective study of 200 patients. Ann Intern Med 80: 205-208
5. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Muller S, Klebl B, Cotten M, Keri G, Wissing J, Daub H (2005) Cellular targets of gefitinib. Cancer Res 65: 379-382
6. Burtis WJ, Wu TL, Insogna KL, Stewart AF (1988) Humoral hypercalcemia of malignancy. Ann Intern Med 108: 454-457
7. Cho YM, Lewis DA, Koltz PF, Richard V, Gocken TA, Rosol TJ, Konger RL, Spandau DF, Foley J (2004) Regulation of parathyroid hormone-related protein gene expression by epidermal growth factor-family ligands in primary human keratinocytes. J Endocrinol 181: 179-190
8. Ciardiello F, Kim N, McGeady ML, Liscia DS, Saeki T, Bianco C, Salomon DS (1991) Expression of transforming growth factor alpha (TGF alpha) in breast cancer. Ann Oncol 2: 169-182
9. Foley J, King CS, Jimenez JA, Wysolmerski JJ, Philbrick WM (2000) Activation of PTHrP gene expression in squamous carcinoma cell lines by mutant isoforms of the tumor suppressor p53. Oncol Res 12: 71-81
10. Franklin WA, Veve R, Hirsch FR, Helfrich BA, Bunn PA (2002) Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 29: 3-14
11. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246
12. Gatza ML, Watt JC, Marriott SJ (2003) Cellular transformation by the HTLV-I Tax protein, a jack-of-all-trades. Oncogene 22: 5141-5149
13. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 22: 777-784
14. Gilmore JL, Riese II DJ (2004) secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation. Oncol Res 14: 589-602
15. Guise TA, Yoneda T, Yates AJ, Mundy GR (1993) The combined effect of tumor-produced parathyroid hormone-related protein and transforming growth factor-alpha enhance hypercalcemia in vivo and bone resorption in vitro. J Clin Endocrinol Metab 77: 40-45
16. Heath JK, Southby J, Fukumoto S, O'Keeffe LM, Martin TJ, Gillespie MT (1995) Epidermal growth factor-stimulated parathyroid hormone-related protein expression involves increased gene transcription and mRNA stability. Biochem J 307(Part 1): 159-167
17. Iguchi H, Tanaka S, Ozawa Y, Kashiwakuma T, Kimura T, Hiraga T, Ozawa H, Kono A (1996) An experimental model of bone metastasis by human lung cancer cells: the role of parathyroid hormone-related protein in bone metastasis. Cancer Res 56: 4040-4043
18. Janmaat ML, Giaccone G (2003) Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 8: 576-586
19. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284: 31-53
20. Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y, Guise TA (2002) Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277: 24571-24578
21. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158
22. Kukreja SC, Shevrin DH, Wimbiscus SA, Ebeling PR, Danks JA, Rodda CP, Wood WI, Martin TJ (1988) Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors. J Clin Invest 82: 1798-1802
23. Lazaretti-Castro M, Kayath M, Jamnik S, Santoro IL, Tadokoru H, Vieira JG (1993) [Prevalence of hypercalcemia in patients with lung cancer]. Rev Assoc Med Bras 39: 83-87
24. Li X, Drucker DJ (1994) Parathyroid hormone-related peptide is a downstream target for ras and src activation. J Biol Chem 269: 6263-6266
25. MacLeod RJ, Chattopadhyay N, Brown EM (2003) PTHrP stimulated by the calcium-sensing receptor requires MAP kinase activation. Am J Physiol Endocrinol Metab 284: E435-E442
26. Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey DL, Dunstan CR (1999) A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. J Bone Miner Res 14: 1478-1485
27. Mundy GR, Martin TJ (1982) The hypercalcemia of malignancy: pathogenesis and management. Metabolism 31: 1247-1277
28. Normanno N, Bianco C, De Luca A, Salomon DS (2001) The role of EGF-related peptides in tumor growth. Front Biosci 6: D685-D707
29. Onuma E, Tsunenari T, Saito H, Sato K, Yamada-Okabe H, Ogata E (2005) Parathyroid hormone-related protein (PTHrP) as a causative factor of cancer-associated wasting: possible involvement of PTHrP in the repression of locomotor activity in rats bearing human tumor xenografts. Int J Cancer 116: 471-478
30. Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, Heimburger DC, Grizzle WE (2002) Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res 8: 734-744
31. Prudkin L, Wistuba II (2006) Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. Ann Diagn Pathol 10: 306-315
32. Qi CF, Liscia DS, Normanno N, Merlo G, Johnson GR, Gullick WJ, Ciardiello F, Saeki T, Brandt R, Kim N, Kenny N, Salomon DS (1994) Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas. Br J Cancer 69: 903-910
33. Ruhe JE, Streit S, Hart S, Ullrich A (2006) EGFR signaling leads to downregulation of PTP-LAR via TACE-mediated proteolytic processing. Cell Signal 18: 1515-1527
34. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, Dmitrovsky E (1993) Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53: 2379-2385
35. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232
36. Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Brown EM (2001) Ca(2+)-sensing receptor expression and PTHrP secretion in PC-3 human prostate cancer cells. Am J Physiol Endocrinol Metab 281: E1267-E1274
37. Sato K, Onuma E, Yocum RC, Ogata E (2003) Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody. Semin Oncol 30: 167-173
38. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR (2004) The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 10: 4227s-44232s
39. Tait DL, MacDonald PC, Casey ML (1994) Parathyroid hormone-related protein expression in gynecic squamous carcinoma cells. Cancer 73: 1515-1521
40. Tfelt-Hansen J, Ferreira A, Yano S, Kanuparthi D, Romero JR, Brown EM, Chattopadhyay N (2005a) Calcium-sensing receptor activation induces nitric oxide production in H-500 Leydig cancer cells. Am J Physiol Endocrinol Metab 288: E1206-E1213
41. Tfelt-Hansen J, MacLeod RJ, Chattopadhyay N, Yano S, Quinn S, Ren X, Terwilliger EF, Schwarz P, Brown EM (2003) Calcium-sensing receptor stimulates PTHrP release by pathways dependent on PKC, p38 MAPK, JNK, and ERK1/2 in H-500 cells. Am J Physiol Endocrinol Metab 285: E329-E337
42. Tfelt-Hansen J, Yano S, John Macleod R, Smajilovic S, Chattopadhyay N, Brown EM (2005b) High calcium activates the EGF receptor potentially through the calcium-sensing receptor in Leydig cancer cells. Growth Factors 23: 117 -123
43. Trapani JA (2005) The dual adverse effects of TGF-beta secretion on tumor progression. Cancer Cell 8: 349-350
44. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353: 133-144
45. Wakeling AE (2002) Epidermal growth factor receptor tyrosine kinase inhibitors. Curr Opin Pharmacol 2: 382-387
46. Wimalawansa SJ (1994) Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 73: 2223-2230
47. Wysolmerski JJ, Vasavada R, Foley J, Weir EC, Burtis WJ, Kukreja SC, Guise TA, Broadus AE, Philbrick WM (1996) Transactivation of the PTHrP gene in squamous carcinomas predicts the occurrence of hypercalcemia in athymic mice. Cancer Res 56: 1043-1049
48. Yan Y, Shirakabe K, Werb Z (2002) The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J Cell Biol 158: 221-226
49. Yano S, Macleod RJ, Chattopadhyay N, Tfelt-Hansen J, Kifor O, Butters RR, Brown EM (2004) Calcium-sensing receptor activation stimulates parathyroid hormone-related protein secretion in prostate cancer cells: role of epidermal growth factor receptor transactivation. Bone 35: 664-672
50. Yarden Y (2001) The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(Suppl 4): S3-S8